Nadia Birocco
Overview
Explore the profile of Nadia Birocco including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
232
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Manzini P, Ciccone G, De Rosa F, Cavallo R, Ghisetti V, DAntico S, et al.
BMC Infect Dis
. 2022 Nov;
22(1):879.
PMID: 36418984
Background: The efficacy of early treatment with convalescent plasma in patients with COVID-19 is debated. Nothing is known about the potential effect of other plasma components other than anti-SARS-CoV-2 antibodies....
2.
Metovic J, La Salvia A, Rapa I, Napoli F, Birocco N, Pia Bizzi M, et al.
Endocr Pathol
. 2022 May;
33(3):388-399.
PMID: 35608806
Extra-pulmonary neuroendocrine carcinomas (EPNEC) represent a group of rare and heterogenous neoplasms with adverse clinical outcome. Their molecular profile is largely unexplored. Our aim was to investigate if the major...
3.
Santoro F, Maletta F, Parente R, Fissore J, Tampieri C, Santoro L, et al.
Endocr Pathol
. 2022 May;
33(2):289-303.
PMID: 35551625
Merkel cell carcinoma is a rare and aggressive primary neuroendocrine carcinoma of the skin, whose pathogenesis can be traced back to UV radiation damage or Merkel cell polyomavirus (MCPyV) infection....
4.
Axfors C, Janiaud P, Schmitt A, Vant Hooft J, Smith E, Haber N, et al.
BMC Infect Dis
. 2021 Nov;
21(1):1170.
PMID: 34800996
Background: Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of...
5.
Ghiggia A, Bianco A, Castelli L, Baratta F, Birocco N, Scaldaferri M, et al.
Eur J Cancer Care (Engl)
. 2020 Oct;
30(1):e13336.
PMID: 33006220
Objective: To evaluate the efficacy of a reinforcement message (RM) administered by a hospital pharmacist on adherence, through a randomised study involving patients undergoing oral chemotherapy from which an objective...
6.
Pelosi G, Massa F, Gatti G, Righi L, Volante M, Birocco N, et al.
Clin Pathol
. 2019 May;
12:2632010X19829259.
PMID: 31041430
Accrual of metastatic pulmonary carcinoid patients for therapy is usually relied on clinical and histologic characterization, with no role for the proliferation activity as defined by Ki-67 labelling index (LI)....
7.
Spadi R, Brusa F, Ponzetti A, Chiappino I, Birocco N, Ciuffreda L, et al.
World J Clin Oncol
. 2016 Feb;
7(1):27-43.
PMID: 26862489
Pancreatic cancer (PC) would become the second leading cause of cancer death in the near future, despite representing only 3% of new cancer diagnosis. Survival improvement will come from a...
8.
Volante M, Monica V, Birocco N, Brizzi M, Busso S, Daniele L, et al.
Neuroendocrinology
. 2015 Jan;
101(2):151-60.
PMID: 25633872
Background: Mixed neuroendocrine/nonneuroendocrine carcinomas are heterogeneous tumors with poorly defined diagnostic and clinical features and without pathological or molecular markers of prognosis or markers predicting their response to therapy. We...
9.
Berruti A, Fazio N, Ferrero A, Brizzi M, Volante M, Nobili E, et al.
BMC Cancer
. 2014 Mar;
14:184.
PMID: 24628963
Background: We assessed the activity and toxicity of the XELBEVOCT regimen in patients with metastatic well-to-moderately differentiated neuroendocrine neoplasms (WMD-NEN). Ancillary studies evaluated hypertension, proteinuria, and vascular endothelial growth factor...
10.
Volante M, Birocco N, Gatti G, Duregon E, Lorizzo K, Fazio N, et al.
Hum Pathol
. 2013 Jun;
45(4):665-73.
PMID: 23806528
Extrapulmonary neuroendocrine carcinoma (EPNEC) is a heterogeneous and rare group of high-grade neoplasms occurring in different organs. They usually share a poor prognosis, but diagnostic and therapeutic options still include...